Delaware | 001-15281 | 76-0233274 | ||
(State or other jurisdiction of | (Commission File Number) | (I.R.S. Employer Identification No.) | ||
incorporation) |
o | Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
o | Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
o | Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
o | Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Item 8.01 Other Information | ||||||||
Item 9.01 Financial Statements and Exhibits | ||||||||
SIGNATURES | ||||||||
EXHIBIT INDEX | ||||||||
Press Release |
Item 8.01 | Other Information. |
Item 9.01 | Financial Statements and Exhibits. |
Exhibit | ||||
Number | Description | |||
99.1 | Press Release dated August 21, 2008 |
Repros Therapeutics Inc. |
||||
Date: August 21, 2008 | By: | /s/ Louis Ploth, Jr. | ||
Louis Ploth, Jr. | ||||
Vice President, Business Development and Chief Financial Officer |
||||